SLDX
Stella Diagnostics, Inc., a molecular diagnostics-based company, focuses on enhancing patient management strategies for people living with severe esophageal diseases. Its clinical assays offer physicians insight into the molecular properties of patients' tissue to determine if the disease is stable, progressing, or turning cancerous. The company is also developing diagnostic tools that provides molecular information for providers as compared to the screening protocols. The company was formerly known as JMP Properties, Inc. and changed its name to Stella Diagnostics, Inc. in April 2021. Stella Diagnostics, Inc. is based in Salt Lake City, Utah.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q4 | -0.01 | $491,535 | -$425,540 |
| 2025 Q3 | -0.00 | $516,707 | -$250,390 |
| 2025 Q2 | -0.00 | $574,313 | -$307,850 |
| 2025 Q1 | -0.00 | $201,262 | -$316,220 |
| 2024 Q4 | -0.00 | $0 | $637,960 |
| 2024 Q3 | -0.00 | $0 | -$53,390 |
| 2024 Q2 | -0.00 | $0 | -$42,450 |
| 2024 Q1 | -0.00 | $0 | -$599,860 |